AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

30/09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
31/26/31	€0.7170	-1.10%
28/26/28	€0.7250	+2.40%
27/26/27	€0.7080	-3.28%
26/26/26	€0.7320	+9.91%
25/26/25	€0.6660	-2.77%

Delayed Quote Deutsche Boerse AG

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Deutsche Boerse AG 11:39:54 31/08/2026 am IST			5-day change	1st Jan Change
0.7170 ^EUR	-1.10%		+4.67%	-47.43%

17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT

Market Cap	5.63Cr 6.53Cr 5.28Cr 4.82Cr 9.05Cr 622.02Cr 9.12Cr 63Cr 24Cr 315.6Cr 25Cr 24Cr 1.04TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.63Cr 6.53Cr 5.28Cr 4.82Cr 9.05Cr 622.02Cr 9.12Cr 63Cr 24Cr 315.6Cr 25Cr 24Cr 1.04TCr	EV / Sales 2026 *	46.9x	EV / Sales 2027 *	43.3x
Free-Float	69.03%	Yield 2026 *	-	Yield 2027 *	-

17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
10/08	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
04/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

AB Science Share Price Deutsche Boerse AG

Stocks

A8D

FR0010557264

Pharmaceuticals

Valuation : AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript : AB Science

Press Releases : AB Science

News in other languages : AB Science

Quotes and Performance

Price Extremes

Managers and Directors : AB Science

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

24/08	AB Science : Franchissement de seuils et déclaration d'intention
17/08	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
17/08	AB Science procède au règlement-livraison de son placement privé
17/08	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
17/08	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026

1 day	-1.10%
1 week	+4.67%
Current month	+34.52%
1 month	+34.52%
3 months	-24.68%
6 months	-44.42%
Current year	-47.43%

1 week	0.67	0.73
1 month	0.54	0.98
Current year	0.52	1.55
1 year	0.52	1.55
3 years	0.52	3.88
5 years	0.52	14.53
10 years	0.52	20.1

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	65	27/06/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-1.10%	+4.67%	-	-	6.71Cr
MERCK & CO., INC.	-0.40%	-3.14%	+75.65%	+34.07%	37TCr
MERCK KGAA	-0.89%	+0.43%	+27.87%	-16.27%	7.08TCr
HALOZYME THERAPEUTICS, INC.	+1.08%	-1.98%	+45.20%	+150.21%	1.2TCr
KYOWA KIRIN CO., LTD.	-1.33%	+2.00%	+3.26%	-1.02%	871.75Cr
SK BIOPHARMACEUTICALS CO., LTD.	-0.80%	+4.30%	-11.46%	+0.92%	500.03Cr
YUHAN CORPORATION	-1.41%	+1.70%	-26.26%	+21.05%	459.34Cr
BETTA PHARMACEUTICALS CO., LTD.	-0.14%	-1.37%	-28.57%	+2.92%	316.11Cr
SUPERNUS PHARMACEUTICALS, INC.	+1.10%	-2.00%	-0.74%	+38.85%	254.19Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.27%	-3.75%	-17.97%	-14.26%	207.92Cr
Average	-0.49%	-0.19%	+7.44%	+24.05%	5.28TCr
Weighted average by Cap.	+0.48%	-1.86%	+63.02%	+27.98%

	2026 *	2027 *
Net sales	12L 13.94L 11.27L 10.29L 19.31L 13Cr 19.45L 1.34Cr 51.92L 6.73Cr 52.33L 51.18L 22Cr	13L 15.1L 12.21L 11.15L 20.92L 14Cr 21.07L 1.45Cr 56.25L 7.29Cr 56.69L 55.44L 24Cr
Net income	-	-
Net Debt	-	-